Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Leukemia ; 33(8): 1978-1995, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30718771

RESUMO

The distinct clinical features of myelofibrosis (MF) have been attributed in part to dysregulated inflammatory cytokine production. Circulating cytokine levels are elevated in MF patients; a subset of which have been shown to be poor prognostic indicators. In this study, cytokine overproduction was examined in MF patient plasma and in MF blood cells ex vivo using mass cytometry. Plasma cytokines measured following treatment with ruxolitinib remained markedly abnormal, indicating that aberrant cytokine production persists despite therapeutic JAK2 inhibition. In MF patient samples, 14/15 cytokines measured by mass cytometry were found to be constitutively overproduced, with the principal cellular source for most cytokines being monocytes, implicating a non-cell-autonomous role for monocyte-derived cytokines impacting disease-propagating stem/progenitor cells in MF. The majority of cytokines elevated in MF exhibited ex vivo hypersensitivity to thrombopoietin (TPO), toll-like receptor (TLR) ligands, and/or tumor necrosis factor (TNF). A subset of this group (including TNF, IL-6, IL-8, IL-10) was minimally sensitive to ruxolitinib. All TPO/TLR/TNF-sensitive cytokines, however, were sensitive to pharmacologic inhibition of NFκB and/or MAP kinase signaling. These results indicate that NFκB and MAP kinase signaling maintain cytokine overproduction in MF, and that inhibition of these pathways may provide optimal control of inflammatory pathophysiology in MF.


Assuntos
Citocinas/biossíntese , Janus Quinases/fisiologia , Sistema de Sinalização das MAP Quinases/fisiologia , NF-kappa B/fisiologia , Mielofibrose Primária/imunologia , Fatores de Transcrição STAT/fisiologia , Transdução de Sinais/fisiologia , Humanos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Monócitos/imunologia , NF-kappa B/antagonistas & inibidores , Nitrilas , Mielofibrose Primária/tratamento farmacológico , Pirazóis/uso terapêutico , Pirimidinas , Trombopoetina/farmacologia , Receptores Toll-Like/fisiologia
3.
Cell ; 175(4): 1014-1030.e19, 2018 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-30343900

RESUMO

Although current immune-checkpoint therapy (ICT) mainly targets lymphoid cells, it is associated with a broader remodeling of the tumor micro-environment. Here, using complementary forms of high-dimensional profiling, we define differences across all hematopoietic cells from syngeneic mouse tumors during unrestrained tumor growth or effective ICT. Unbiased assessment of gene expression of tumor-infiltrating cells by single-cell RNA sequencing (scRNAseq) and longitudinal assessment of cellular protein expression by mass cytometry (CyTOF) revealed significant remodeling of both the lymphoid and myeloid intratumoral compartments. Surprisingly, we observed multiple subpopulations of monocytes/macrophages, distinguishable by the markers CD206, CX3CR1, CD1d, and iNOS, that change over time during ICT in a manner partially dependent on IFNγ. Our data support the hypothesis that this macrophage polarization/activation results from effects on circulatory monocytes and early macrophages entering tumors, rather than on pre-polarized mature intratumoral macrophages.


Assuntos
Linfócitos/imunologia , Células Mieloides/imunologia , Neoplasias/imunologia , Análise de Célula Única , Transcriptoma , Animais , Linhagem Celular Tumoral , Citometria de Fluxo , Imunoterapia/métodos , Interferon gama/imunologia , Ativação de Macrófagos , Masculino , Espectrometria de Massas , Camundongos , Células Precursoras de Monócitos e Macrófagos/imunologia , Neoplasias/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA